Recombinant yellow fever viruses are effective therapeutic vaccines for treatment of murine experimental solid tumors and pulmonary metastases

Journal of Virology

Volumn 74, Issue 19, 2000, Pages 9197-9205

  McAllister, A ^a   Arbetman, A E ^a   Mandl, S ^a   Pena Rossi, C ^a   Andino, R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; LIVE VACCINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; OVALBUMIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; ARTICLE; CANCER IMMUNIZATION; CANCER REGRESSION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; GENETIC ENGINEERING; HUMAN; HUMAN CELL; LUNG METASTASIS; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; STRAIN DIFFERENCE; TREATMENT OUTCOME; TUMOR IMMUNITY; VIRUS RECOMBINANT; VIRUS REPLICATION; YELLOW FEVER FLAVIVIRUS;

ANIMAL; CANCER VACCINES; CYTOTOXICITY, IMMUNOLOGIC; EPITOPES, T-LYMPHOCYTE; IMMUNOTHERAPY; LUNG NEOPLASMS; MICE; NEOPLASMS, EXPERIMENTAL; SUPPORT, U.S. GOV'T, P.H.S.; VACCINES, SYNTHETIC; VIRAL VACCINES; YELLOW FEVER VIRUS;

EID: 0033803502     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.74.19.9197-9205.2000     Document Type: Article

References (54)

1. Dicistronic polioviruses as expression vectors for foreign genes
2. Phenotypic analysis of antigen-specific T lymphocytes
3. Characterization of a membrane-bound metalloendoprotease of rat C6 glioblastoma cells
4. Fatal viral encephalitis following 17D yellow fever vaccine inoculation. Report of a case in a 3-year-old child
5. Engineering poliovirus as a vaccine vector for the expression of diverse antigens
6. Interferon regulates expression of mda-6/WAF1/CIP1 and cyclin-dependent kinases independently from p53 in B16 routine melanoma cells
7. Lack of mda-6/WAF1/CIP1-mediated inhibition of cyclin-dependent kinases in interferon-alpha resistant routine B16 melanoma cells
8. T cell-mediated, IFN-gamma-facilitated rejection of routine B16 melanomas
9. Tumor antigens recognized by cytolytic T lymphocytes: Present perspectives for specific immunotherapy
10. Identification of tumour rejection antigens recognized by T lymphocytes
11. Antigen chimeras of poliovirus
12. Highly attenuated modified vaccinia virus Ankara (MVA) as an effective recombinant vector: A routine tumor model
13. Processing of the yellow fever virus nonstructural polyprotein: A catalytically active NS3 proteinase domain and NS2B are required for cleavages at dibasic sites
14. Yellow fever/Japanese encephalitis chimeric viruses: Construction and biological properties
15. Evidence that the N-terminal domain of nonstructural protein NS3 from yellow fever virus is a serine protease responsible for site-specific cleavages in the viral polyprotein
16. Therapeutic antitumor response after immunization with a recombinant adenovirus encoding a model tumor-associated antigen
17. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction
18. Resistance to melanoma in mice immunized with semiallogeneic fibroblasts transfected with DNA from mouse melanoma cells
19. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity
20. A phase I study of vaccination with autologous, irradiated melanoma cells engineered to secrete human granulocyte-macrophage colony stimulating factor
21. A case report: Immune responses and clinical course of the first human use of granulocyte/macrophage-colony-stimulating-factor-transduced autologous melanoma cells for immunotherapy
22. Targeting antigen into the phagocytic pathway in vivo induces protective tumour immunity
23. Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates
24. Immunogenicity, genetic stability, and protective efficacy of a recombinant, chimeric yellow fever-Japanese encephalitis virus (ChimeriVax-JE) as a live, attenuated vaccine candidate against Japanese encephalitis
25. Detection of rare antigen-presenting cells by the lacZ T-cell activation assay suggests an expression cloning strategy for T-cell antigens
26. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor
27. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection
28. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes
29. Subgenomic replicons of the flavivirus Kunjin: Construction and applications
30. Potentiation of antitumor effects of tumor necrosis factor alpha and interferon gamma by macrophage-colony-stimulating factor in a MmB16 melanoma model in mice
31. Construction and genetic analysis of dicistronic polioviruses containing open reading frames for epitopes of human immunodeficiency virus type 1 gp120
32. Poliovirus vaccine vectors elicit antigen-specific cytotoxic T cells and protect mice against lethal challenge with malignant melanoma cells expressing a model antigen
33. Flaviviruses
34. Yellow fever: Victor, Victoria? Conqueror, conquest? Epidemics and research in the last forty years and prospects for the future
35. Chimeric yellow fever virus 17D-Japanese encephalitis virus vaccine: Dose-response effectiveness and extended safety testing in rhesus monkeys
36. Should yellow fever vaccine be included in the expanded program of immunization in Africa? A cost-effectiveness analysis for Nigeria
37. Recombinant, chimaeric live, attenuated vaccine (ChimeriVax) incorporating the envelope genes of Japanese encephalitis (SA14-14-2) virus and the capsid and nonstructural genes of yellow fever (17D) virus is safe, immunogenic and protective in non-human primates
38. Expression of foreign proteins by polio-virus polyprotein fusion: Analysis of genetic stability reveals rapid deletions and formation of cardioviruslike open reading frames
39. Vaccination with a recombinant vaccinia virus encoding a 'self' anti-gen induces autoimmune vitiligo and tumor cell destruction in mice: Requirement for CD4(+) T lymphocytes
40. Persistence of neutralizing antibody 30-35 years after immunization with 17D yellow fever vaccine
41. The pathogenesis of cancer metastasis
42. Development of viremia and humoral and cellular parameters of immune activation after vaccination with yellow fever virus strain 17D: A model of human flavivirus infection
43. The new vaccines: Building viruses that elicit antitumor immunity
44. Transfectant influenza A viruses are effective recombinant immunogens in the treatment of experimental cancer
45. Transcription of infectious yellow fever RNA from full-length cDNA templates produced by in vitro ligation
46. Immunization with a vaccinia virus recombinant expressing herpes simplex virus type 1 glycoprotein D: Long-term protection and effect of revaccination
47. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2
48. Isolation and analysis of naturally processed viral peptides as recognized by cytotoxic T cells
49. Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer
50. Polio-virus RNA recombination in cell-free extracts
51. Noncytopathic flavivirus replicon RNA-based system for expression and delivery of heterologous genes
52. Flavivirus replication strategy
53. Yellow fever 17D vaccine virus isolated from healthy vaccinees accumulates very few mutations
54. Immunotherapeutic potential of tumor antigen-pulsed and unpulsed dendritic cells generated from murine bone marrow